Adoptive cellular immunotherapy for the treatment of patients with breast cancer: A meta-analysis |
| |
| Affiliation: | 1. Department of Ultrasound, Shenzhen Guangming New District People’s Hospital, 339# Songbai road, Gongming Street, Shenzhen 518106, China;2. No. 2 Clinic, Logistic Support Department, Central Military Commission, People''s Republic of China, Beijing 100071, China;3. Department of Ultrasound, South Building, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China;4. Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital, Beijing, 100853, PR China;1. Department of Digestive, Ruikang Affiliated Hospital of Guangxi, University of Chinese Medicine, 530011 Huadong Road No. 10, Nanning, 530023 Guangxi, China;2. Department of Hepatopathy, The First Affiliated Hospital of Guangxi, University of Chinese Medicine, Dongge Road No. 89-9, 530023 Nanning, China;1. The Central Laboratory, Guangming New District People''s Hospital, Shenzhen, China;2. School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan, China;3. Institute of Virology, School of Medicine, State Key Laboratory of Virology, Wuhan University, Wuhan, China;4. Hubei Collaborative Innovation Center for Green Transformation of Bio-resources, College of Life Sciences, Hubei University, Wuhan, China;5. Department of Laboratory Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China |
| |
| Abstract: | ![]()
BackgroundTo evaluate the therapeutic efficacy of dendritic cells (DC) alone, cytokine-induced killer (CIK) cells alone and the combination of DC and CIK cells in the treatment of breast cancer, we performed a systemic review of the relevant published clinical studies, collectively referred to as DC-CIK cell therapy.MethodsSix hundred thirty-three patients with breast cancer were assigned to cohorts, and a meta-analysis was conducted.ResultsThe treatment of breast cancer with DC-CIK cells was associated with a significantly improved 1-year survival (P = 0.0001). The Karnofsky performance status scale of the patients treated with DC-CIK cells was significantly improved compared with that of the non-DC-CIK group (P < 0.0001). The percentage of T cells (CD3+, CD4+ and CD4+CD8+), CD16+ monocytes, and CD3+CD56+ natural killer T cells in the peripheral blood of cancer patients was significantly increased (P ≤ 0.05), whereas the percentage of CD4+CD25+ regulatory T cells was not significantly decreased (P = 0.32) in the DC-CIK treatment group compared with the non-DC-CIK group. The levels of interleukin-2, interleukin-12, tumor necrosis factor-α, interferon-γ, and nucleolar organizer region protein in the peripheral blood of cancer patients, which reflect immune function, were significantly increased (P < 0.001) after DC-CIK cell treatment. Furthermore, after DC-CIK treatment, the average levels of the alpha-fetoprotein, cancer antigen embryonic antigen and carbohydrate antigen tumor markers were decreased (P < 0.00001).ConclusionsDC-CIK cell therapy markedly prolongs survival time, enhances immune function, and improves the efficacy of the treatment of breast cancer patients. |
| |
| Keywords: | breast cancer cytokine-induced killer cells dendritic cells immunotherapy meta-analysis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
